韩国大规模化学预防下氯喹治疗间日疟原虫的疗效与 pvmdr1 多态性。
Therapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis.
机构信息
Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Kangwon-do, Republic of Korea.
出版信息
Am J Trop Med Hyg. 2011 Apr;84(4):532-4. doi: 10.4269/ajtmh.2011.10-0486.
Abstract
Chemoprophylaxis with hydroxychloroquine (HCQ) and primaquine has been used in the Republic of Korea (ROK) Army since 1997. It may facilitate the development of chloroquine (CQ)-resistant strains of Plasmodium vivax. We investigated the therapeutic efficacy of HCQ and the pvmdr1 gene polymorphisms in P. vivax. From June to September 2006, 102 soldiers with vivax malaria near the demilitarized zone in Gyeonggi-do, ROK, were enrolled in the study. We determined the status of compliance of chemoprophylaxis. In 85 patients, therapeutic efficacy was monitored 28 days after standard HCQ treatment; 66 (64.7%) of 102 malaria patients had taken all chemoprolaxis with HCQ. In all patients enrolled in the therapeutic efficacy monitoring, parasitemia had not been observed since 3 days after standard HCQ treatment. However, the ubiquitous presence of the F1076L mutation of the pvmdr1 was observed. There was no evidence that the F1076L mutation of pvmdr1 could contribute to failure of HCQ treatment.
摘要
自 1997 年以来，羟氯喹（HCQ）和伯氨喹联合化学预防方案一直在韩国军队中使用。它可能会促进恶性疟原虫对氯喹（CQ）的耐药株的产生。我们调查了 HCQ 治疗效果和恶性疟原虫 pvmdr1 基因多态性。2006 年 6 月至 9 月，102 名在京畿道非军事区附近患有间日疟的士兵参加了这项研究。我们确定了化学预防的用药依从性。在 85 名接受标准 HCQ 治疗的患者中，监测了 28 天的治疗效果；102 例疟疾病例中 66 例（64.7%）患者均按规定服用了 HCQ 预防药物。在所有接受治疗效果监测的患者中，自标准 HCQ 治疗后 3 天起，均未观察到寄生虫血症。然而，普遍存在恶性疟原虫 pvmdr1 的 F1076L 突变。没有证据表明 pvmdr1 的 F1076L 突变会导致 HCQ 治疗失败。
相似文献
1
Therapeutic efficacy of chloroquine in Plasmodium vivax and the pvmdr1 polymorphisms in the Republic of Korea under mass chemoprophylaxis.韩国大规模化学预防下氯喹治疗间日疟原虫的疗效与 pvmdr1 多态性。
Am J Trop Med Hyg. 2011 Apr;84(4):532-4. doi: 10.4269/ajtmh.2011.10-0486.
2
Evaluation of single nucleotide polymorphisms of pvmdr1 and microsatellite genotype in Plasmodium vivax isolates from Republic of Korea military personnel.韩国军人间日疟原虫分离株中pvmdr1单核苷酸多态性及微卫星基因型的评估
Malar J. 2015 Sep 4;14:336. doi: 10.1186/s12936-015-0845-6.
3
In vivo therapeutic efficacy of chloroquine alone or in combination with primaquine against vivax malaria in Kolkata, West Bengal, India, and polymorphism in pvmdr1 and pvcrt-o genes.印度西孟加拉邦加尔各答地区氯喹单药或联合伯氨喹治疗间日疟的体内疗效及 pvmdr1 和 pvcrt-o 基因多态性。
Antimicrob Agents Chemother. 2013 Mar;57(3):1246-51. doi: 10.1128/AAC.02050-12. Epub 2012 Dec 21.
4
Plasmodium vivax resistance to chloroquine in Madagascar: clinical efficacy and polymorphisms in pvmdr1 and pvcrt-o genes.马达加斯加间日疟原虫对氯喹的耐药性：pvmdr1和pvcrt - o基因的临床疗效及多态性
Antimicrob Agents Chemother. 2008 Dec;52(12):4233-40. doi: 10.1128/AAC.00578-08. Epub 2008 Sep 22.
5
Biological resistance of hydroxychloroquine for Plasmodium vivax malaria in the Republic of Korea.韩国间日疟原虫疟疾对羟氯喹的生物学抗性
Am J Trop Med Hyg. 2009 Oct;81(4):600-4. doi: 10.4269/ajtmh.2009.09-0102.
6
Short report: chloroquine-resistant Plasmodium vivax in the Republic of Korea.简短报告：韩国出现抗氯喹间日疟原虫
Am J Trop Med Hyg. 2009 Feb;80(2):215-7.
7
Plasmodium vivax malaria: status in the Republic of Korea following reemergence.间日疟原虫疟疾：在韩国再度出现后的现状
Korean J Parasitol. 2009 Oct;47 Suppl(Suppl):S39-50. doi: 10.3347/kjp.2009.47.S.S39.
8
Prevalence and patterns of antifolate and chloroquine drug resistance markers in Plasmodium vivax across Pakistan.在巴基斯坦，恶性疟原虫对抗叶酸和氯喹药物耐药标志物的流行情况和模式。
Malar J. 2013 Sep 5;12:310. doi: 10.1186/1475-2875-12-310.
9
Characterization of Polymorphisms in Isolates from Mangaluru, India.印度芒格洛尔分离株的多态性特征。
Am J Trop Med Hyg. 2019 Aug;101(2):416-417. doi: 10.4269/ajtmh.19-0224.
10
Genetic polymorphism in pvmdr1 and pvcrt-o genes in relation to in vitro drug susceptibility of Plasmodium vivax isolates from malaria-endemic countries.pvmdr1 和 pvcrt-o 基因的遗传多态性与来自疟疾流行国家的间日疟原虫分离株的体外药物敏感性有关。
Acta Trop. 2011 Feb;117(2):69-75. doi: 10.1016/j.actatropica.2010.08.011. Epub 2010 Oct 8.
引用本文的文献
1
Molecular epidemiology of potential candidate markers for chloroquine resistance in imported Plasmodium vivax malaria cases in Iran.伊朗输入性间日疟原虫对氯喹耐药的潜在候选标志物的分子流行病学研究。
Malar J. 2023 Apr 10;22(1):118. doi: 10.1186/s12936-023-04553-y.
2
Prevalence and temporal changes of mutations linked to antimalarial drug resistance in Plasmodium falciparum and Plasmodium vivax in Palawan, Philippines.菲律宾巴拉望岛疟原虫和间日疟原虫抗疟药物耐药相关突变的流行率和时间变化。
Int J Infect Dis. 2022 Mar;116:174-181. doi: 10.1016/j.ijid.2021.12.318. Epub 2021 Dec 7.
3
Ten-Year Molecular Surveillance of Drug-Resistant spp. Isolated From the China-Myanmar Border.十年间中缅边境地区耐多药 分离株的分子监测
Front Cell Infect Microbiol. 2021 Sep 1;11:733788. doi: 10.3389/fcimb.2021.733788. eCollection 2021.
4
Molecular surveillance for drug resistance markers in Plasmodium vivax isolates from symptomatic and asymptomatic infections at the China-Myanmar border.中缅边境地区有症状和无症状感染的间日疟原虫分离株中耐药标志物的分子监测。
Malar J. 2020 Aug 5;19(1):281. doi: 10.1186/s12936-020-03354-x.
5
Assessment of drug resistance associated genetic diversity in Mauritanian isolates of Plasmodium vivax reveals limited polymorphism.评估来自毛里塔尼亚的间日疟原虫分离株的耐药相关遗传多样性揭示了有限的多态性。
Malar J. 2018 Nov 8;17(1):416. doi: 10.1186/s12936-018-2548-2.
6
Malaria control and chemoprophylaxis policy in the Republic of Korea Armed Forces for the previous 20 years (1997-2016).韩国军队过去 20 年（1997-2016 年）的疟疾控制和化学预防政策。
Malar J. 2018 Aug 15;17(1):295. doi: 10.1186/s12936-018-2449-4.
7
Plasmodium vivax multidrug resistance-1 gene polymorphism in French Guiana.法属圭亚那间日疟原虫多药耐药-1基因多态性
Malar J. 2016 Nov 8;15(1):540. doi: 10.1186/s12936-016-1595-9.
8
Diagnosis and Treatment of Plasmodium vivax Malaria.间日疟的诊断与治疗
Am J Trop Med Hyg. 2016 Dec 28;95(6 Suppl):35-51. doi: 10.4269/ajtmh.16-0171. Epub 2016 Oct 5.
9
Multiple Origins of Mutations in the mdr1 Gene--A Putative Marker of Chloroquine Resistance in P. vivax.间日疟原虫中mdr1基因的多个突变起源——氯喹抗性的一个假定标志物
PLoS Negl Trop Dis. 2015 Nov 5;9(11):e0004196. doi: 10.1371/journal.pntd.0004196. eCollection 2015 Nov.
10
Evaluation of single nucleotide polymorphisms of pvmdr1 and microsatellite genotype in Plasmodium vivax isolates from Republic of Korea military personnel.韩国军人间日疟原虫分离株中pvmdr1单核苷酸多态性及微卫星基因型的评估
Malar J. 2015 Sep 4;14:336. doi: 10.1186/s12936-015-0845-6.
本文引用的文献
1
Biological resistance of hydroxychloroquine for Plasmodium vivax malaria in the Republic of Korea.韩国间日疟原虫疟疾对羟氯喹的生物学抗性
Am J Trop Med Hyg. 2009 Oct;81(4):600-4. doi: 10.4269/ajtmh.2009.09-0102.
2
Amplification of pvmdr1 associated with multidrug-resistant Plasmodium vivax.与耐多药间日疟原虫相关的pvmdr1基因扩增。
J Infect Dis. 2008 Nov 15;198(10):1558-64. doi: 10.1086/592451.
3
Chloroquine resistant Plasmodium vivax: in vitro characterisation and association with molecular polymorphisms.氯喹耐药间日疟原虫：体外特性及其与分子多态性的关联
PLoS One. 2007 Oct 31;2(10):e1089. doi: 10.1371/journal.pone.0001089.
4
Evaluation of anti-malarial effects of mass chemoprophylaxis in the Republic of Korea army.韩国军队大规模化学预防疟疾效果评估。
J Korean Med Sci. 2005 Oct;20(5):707-12. doi: 10.3346/jkms.2005.20.5.707.
5
Status of Plasmodium vivax malaria in the Republic of Korea during 2001-2003.2001 - 2003年期间韩国间日疟原虫疟疾的状况
Am J Trop Med Hyg. 2005 Sep;73(3):604-8.
6
Plasmodium vivax: allele variants of the mdr1 gene do not associate with chloroquine resistance among isolates from Brazil, Papua, and monkey-adapted strains.间日疟原虫：来自巴西、巴布亚的分离株以及猴适应株中，mdr1基因的等位基因变体与氯喹抗性无关。
Exp Parasitol. 2005 Apr;109(4):256-9. doi: 10.1016/j.exppara.2004.12.005.
7
Absence of nucleotide polymorphism in a Plasmodium vivax multidrug resistance gene after failure of mefloquine prophylaxis in French Guyana.在法属圭亚那甲氟喹预防失败后，间日疟原虫多药耐药基因中不存在核苷酸多态性。
Trans R Soc Trop Med Hyg. 2005 Mar;99(3):234-7. doi: 10.1016/j.trstmh.2004.09.007.
8
Identification of the Plasmodium vivax mdr-like gene (pvmdr1) and analysis of single-nucleotide polymorphisms among isolates from different areas of endemicity.间日疟原虫多药耐药样基因（pvmdr1）的鉴定及不同流行地区分离株单核苷酸多态性分析。
J Infect Dis. 2005 Jan 15;191(2):272-7. doi: 10.1086/426830. Epub 2004 Dec 9.
9
Chloroquine resistance in Plasmodium vivax.间日疟原虫的氯喹耐药性
Antimicrob Agents Chemother. 2004 Nov;48(11):4075-83. doi: 10.1128/AAC.48.11.4075-4083.2004.
10
Primaquine therapy for malaria.伯氨喹治疗疟疾。
Clin Infect Dis. 2004 Nov 1;39(9):1336-45. doi: 10.1086/424663. Epub 2004 Oct 12.
Zotero 插件